Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on AmpliPhi Biosciences Corporation
Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.
AmpliPhi Biosciences, (formerly known as Targeted Genetics Corporation), develops gene-based products for the treatment of acquired and inherited diseases. It raised $9.1 million in a secondary public offering, as reported in the PharmSource Lead Sheet on May 11, 2017.
- AmpliPhi Biosciences was incorporated in Washington in March 1989 as a subsidiary of Immunex Corporation, began operations in 1992 and changed its name to AmpliPhi Biosciences in February 2011.
- Corporate Headquarters: San Diego, CA – approximately 1,000 square feet of office space
- Other facilities: Richmond, VA; Brookvale, Australia; Ljubljana, Slovenia
- Stock Exchange: NYSE
- Stock Symbol: APHB
- AmpliPhi Biosciences plans to use the proceeds to fund general corporate purposes, including manufacturing, R&D activities and ongoing clinical trials of its pipeline, which may include:
- AB-PA01 – To complete preclinical studies:
- For treatment of Pseudomonas aeruginosa lung infections in Cystic Fibrosis (CF) patients
- Dosage Form: Intranasal; Topical; Inhaled
- Nature of API: Biologic – Genetically modified virus
- Therapeutic Areas: Antibacterial; Pulmonary
- AB-SA01 – To complete a Phase I study:
- For treatment of Staphylococcus aureus infections
- Dosage Form: Topical; Semi-solid – Non-sterile
- Nature of API: Biologic – Unspecified
- Therapeutic Areas: Antibacterial
- In September 2015, AmpliPhi Biosciences and Takara Bio entered into a patent license agreement where Takara Bio received certain patents related to AAV1 Vector gene delivery systems. AmpliPhi Biosciences received a $40,000 up-front payment and up to $85,000 in royalty and milestone payments.
- In June 2013, AmpliPhi Biosciences and the US Army Medical Research and Materiel Command entered into an agreement for the research and development of bacteriophage therapeutics to treat S. aureus infections. Financial terms were undisclosed.1
Drug Product Pipeline
|Product Candidate||Indication||Dosage Form||Status||Next Anticipated Step|
|AB-PA01||Pseudomonas aeruginosa lung infections in Cystic Fibrosis (CF) patients||Intranasal; Topical; Inhaled||Preclinical||TBA|
|AB-PA01||Pseudomonas aeruginosa lung infections in chronic rhinosinusitis||Intranasal; Topical; Inhaled||Preclinical||TBA|
|AB-SA01||Staphylococcus aureus infections||Topical; Semi-solid – Non-sterile||Phase I||Initiate a Phase II study in 2017|
|AB-SA01||Chronic rhinosinusitis associated with Staphylococcus aureus infection||Intranasal; Topical||Phase I||TBA|
|(In $ thousands)||2016||2015|
|General & Administrative Expenditures|
|Total Operating Expenses|
1AmpliPhi Biosciences Corporation, 3/27/17 10-K, SEC.gov
|AmpliPhi Biosciences Corporation||Key Officers|
|3579 Valley Centre Drive, Suite 100||M. Scott Salka, CEO|
|San Diego, CA, 92130 USA||Barbara Hubad, Manager, Quality Control|
|Phone: +1-858-829-0829||Sandra Morales, Global Head, Research|
|Web: www.ampliphibio.com||Francisco Rosas, Associate Director, Regulatory Affairs|
Follow the Money to Pharmaceutical Opportunities – Spotlight on ContraVir Pharmaceuticals, Inc.
Follow the Money to Pharmaceutical Opportunities – Spotlight on BioCryst Pharmaceuticals, Inc.
Follow the Money to Pharmaceutical Opportunities – Spotlight on Aldeyra Therapeutics, Inc.